Adocia Prioritizes BioChaperone and Secures Cash Reserves Until Early Q2 2027
Adocia has released its Q1 2026 financial results, showing a cash balance of EUR 12.0 million as of March 31, with a quarterly cash burn of EUR 5.1 million. As typical for a clinical-stage biotech, revenue was zero for the period, compared to EUR 0.6 million a year earlier from an AdOral feasibility study. The Lyon-based company is reallocating its resources towards BioChaperone, now a priority following positive feasibility study results, and has suspended the clinical trial application submission for AdoShell. A EUR 6.0 million financing arrangement with Vester Finance extends its cash runway until the start of Q2 2027.
Cash Balance of EUR 12 Million at End of March
Adocia had a cash reserve of EUR 12.0 million on March 31, 2026, down from EUR 17.2 million on December 31, 2025. The cash burn for the first quarter amounted to EUR 5.1 million, compared to EUR 6.6 million in the first quarter of 2025 excluding financing. Revenue for the period was zero, down from EUR 0.6 million a year earlier.
This decline should be viewed in the context of the economic model of a clinical-stage biotech: revenues are inherently irregular and depend largely on partnerships, milestone payments, or feasibility studies. In the first quarter of 2025, revenues came from a feasibility study related to the AdOral technology with an undisclosed partner.
BioChaperone Becomes the Strategic Priority
The major shift announced by Adocia concerns its resource allocation. The company now prioritizes the BioChaperone platform, following positive results from feasibility studies and the initiation of a new study. This platform aims to stabilize and enhance metabolic peptide formulations, in a market where diabetes and obesity treatments are moving towards peptide combinations, particularly involving GLP-1 and amylin. Adocia has initiated feasibility studies with three major undisclosed pharmaceutical companies, two of which have yielded positive results.
AdoShell Suspended, But Not Abandoned
In parallel, Adocia has suspended activities related to the clinical trial application submission for AdoShell with human pancreatic islets, initially planned for the third quarter of 2026. The company explains this decision by the priority given to BioChaperone and the need to reallocate its human and financial resources to this technology. However, the AdoShell program is not presented as abandoned: Adocia indicates that it could resume this clinical goal when its financial situation and human resources allow.
